CliffBio
biologic

Xyntha, Xyntha Solofuse

Antihemophilic Factor (Recombinant), Plasma/Albumin Free

Loss of exclusivityFebruary 2020projected — 12-year biologic exclusivity estimate
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand nameXyntha, Xyntha Solofuse
Active ingredientAntihemophilic Factor (Recombinant), Plasma/Albumin Free
Strength1000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2008
Marketing statusRx

More from Wyeth

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Xyntha, Xyntha Solofuse patent cliff — loss of exclusivity February 2020 | CliffBio